BRPI0507897B1 - formulação de droga sólida - Google Patents
formulação de droga sólida Download PDFInfo
- Publication number
- BRPI0507897B1 BRPI0507897B1 BRPI0507897A BRPI0507897A BRPI0507897B1 BR PI0507897 B1 BRPI0507897 B1 BR PI0507897B1 BR PI0507897 A BRPI0507897 A BR PI0507897A BR PI0507897 A BRPI0507897 A BR PI0507897A BR PI0507897 B1 BRPI0507897 B1 BR PI0507897B1
- Authority
- BR
- Brazil
- Prior art keywords
- fact
- drug formulation
- formulation according
- granular
- drug
- Prior art date
Links
- 239000013583 drug formulation Substances 0.000 title claims abstract description 33
- 239000007787 solid Substances 0.000 title claims abstract description 12
- 239000008187 granular material Substances 0.000 claims abstract description 36
- LUMKNAVTFCDUIE-VHXPQNKSSA-N ospemifene Chemical compound C1=CC(OCCO)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 LUMKNAVTFCDUIE-VHXPQNKSSA-N 0.000 claims abstract description 25
- 229960003969 ospemifene Drugs 0.000 claims abstract description 23
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 22
- 150000003839 salts Chemical class 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 29
- 239000002245 particle Substances 0.000 claims description 25
- 239000003085 diluting agent Substances 0.000 claims description 21
- 239000007884 disintegrant Substances 0.000 claims description 19
- 239000011230 binding agent Substances 0.000 claims description 17
- 238000004090 dissolution Methods 0.000 claims description 16
- 238000009472 formulation Methods 0.000 claims description 16
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 12
- 229940088679 drug related substance Drugs 0.000 claims description 12
- 239000000314 lubricant Substances 0.000 claims description 10
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 9
- 229920002472 Starch Polymers 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 7
- 229940032147 starch Drugs 0.000 claims description 7
- 239000008107 starch Substances 0.000 claims description 7
- 235000019698 starch Nutrition 0.000 claims description 7
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 6
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 6
- 229920001353 Dextrin Polymers 0.000 claims description 6
- 239000004375 Dextrin Substances 0.000 claims description 6
- 229920002774 Maltodextrin Polymers 0.000 claims description 6
- 239000005913 Maltodextrin Substances 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 6
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 6
- 229940105329 carboxymethylcellulose Drugs 0.000 claims description 6
- 235000019425 dextrin Nutrition 0.000 claims description 6
- 238000007908 dry granulation Methods 0.000 claims description 6
- 229940035034 maltodextrin Drugs 0.000 claims description 6
- 229920000609 methyl cellulose Polymers 0.000 claims description 6
- 239000001923 methylcellulose Substances 0.000 claims description 6
- 235000010981 methylcellulose Nutrition 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 229940069328 povidone Drugs 0.000 claims description 6
- 238000005550 wet granulation Methods 0.000 claims description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 4
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 4
- 239000008109 sodium starch glycolate Substances 0.000 claims description 4
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 229930091371 Fructose Natural products 0.000 claims description 3
- 239000005715 Fructose Substances 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 229920002907 Guar gum Polymers 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 240000007472 Leucaena leucocephala Species 0.000 claims description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 3
- 235000021355 Stearic acid Nutrition 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 239000000783 alginic acid Substances 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- 229960001126 alginic acid Drugs 0.000 claims description 3
- 150000004781 alginic acids Chemical class 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 239000001506 calcium phosphate Substances 0.000 claims description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 3
- 235000011010 calcium phosphates Nutrition 0.000 claims description 3
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 3
- 239000008116 calcium stearate Substances 0.000 claims description 3
- 235000013539 calcium stearate Nutrition 0.000 claims description 3
- 239000005018 casein Substances 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 3
- 229960000913 crospovidone Drugs 0.000 claims description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 3
- -1 dextrates Chemical compound 0.000 claims description 3
- 229940096516 dextrates Drugs 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 229960001031 glucose Drugs 0.000 claims description 3
- 235000001727 glucose Nutrition 0.000 claims description 3
- 239000000665 guar gum Substances 0.000 claims description 3
- 235000010417 guar gum Nutrition 0.000 claims description 3
- 229960002154 guar gum Drugs 0.000 claims description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 229960002900 methylcellulose Drugs 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 235000010446 mineral oil Nutrition 0.000 claims description 3
- 239000002480 mineral oil Substances 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 3
- 229960000502 poloxamer Drugs 0.000 claims description 3
- 229920001983 poloxamer Polymers 0.000 claims description 3
- 229920000193 polymethacrylate Polymers 0.000 claims description 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 3
- 229920003124 powdered cellulose Polymers 0.000 claims description 3
- 235000019814 powdered cellulose Nutrition 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 239000008117 stearic acid Substances 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 239000000454 talc Substances 0.000 claims description 3
- 229910052623 talc Inorganic materials 0.000 claims description 3
- 235000012222 talc Nutrition 0.000 claims description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 3
- 239000008158 vegetable oil Substances 0.000 claims description 3
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 2
- 239000012458 free base Substances 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 235000015424 sodium Nutrition 0.000 claims 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 9
- 239000002207 metabolite Substances 0.000 abstract description 7
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 abstract description 6
- 229960005026 toremifene Drugs 0.000 abstract description 4
- 150000002148 esters Chemical class 0.000 abstract description 2
- 239000003826 tablet Substances 0.000 description 30
- 229940079593 drug Drugs 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 238000005469 granulation Methods 0.000 description 9
- 230000003179 granulation Effects 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 6
- 230000001833 anti-estrogenic effect Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 5
- 206010003694 Atrophy Diseases 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 230000037444 atrophy Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000007907 direct compression Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000007922 dissolution test Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000009245 menopause Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000005204 segregation Methods 0.000 description 3
- 229960001603 tamoxifen Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010071018 Urogenital atrophy Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 230000001076 estrogenic effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000013067 intermediate product Substances 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010036018 Pollakiuria Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 206010064921 Urinary tract inflammation Diseases 0.000 description 1
- 208000028938 Urination disease Diseases 0.000 description 1
- 206010047791 Vulvovaginal dryness Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000003262 anti-osteoporosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000028659 discharge Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 229950004203 droloxifene Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000009506 drug dissolution testing Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 201000005630 leukorrhea Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000007896 modified release capsule Substances 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009490 roller compaction Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 208000022934 urinary frequency Diseases 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 230000036318 urination frequency Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 229940057977 zinc stearate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Nomes dos ingredientes | Quantidade (%) GRANULAÇÃO | Quantidade (%) COMPRESSÃO DIRETA | Função | |
Ospemifeno | 30 | 30 | Substância ativa | |
Amido gelatinizado | pré- | 38 | 38 | Diluente |
Amido de milho | 25 | 25 | Diluente | |
Povidona | 2 | 2 | Aglutinante | |
Glicolato de amido de sódio | 4 | 4 | Desintegrante | |
Estearato magnésio | de | 1 | 1 | Lubrificante |
Água, purificada | * | 25 | - | Solvente |
Claims (21)
- REIVINDICAÇÕES1. Formulação de droga sólida, caracterizada pelo fato de que compreende grânulos contendo 30 a 90 mg de ospemifeno ou um sal farmaceuticamente aceitável do mesmo, em combinação com um ou mais excipientes intra-granulares, selecionados de um desintegrante, um diluente, um aglutinante, e combinações destes.
- 2. Formulação de droga, de acordo com a reivindicação 1, caracterizada pelo fato de que o ospemifeno é uma base livre.
- 3. Formulação de droga, de acordo com a reivindicação 1, caracterizada pelo fato de que pelo menos um excipiente intra-granular é um desintegrante.
- 4. Formulação de droga, de acordo com a reivindicação 1, caracterizada pelo fato de que pelo menos um excipiente intra-granular é um diluente.
- 5. Formulação de droga, de acordo com a reivindicação 1, caracterizada pelo fato de que pelo menos um excipiente intra-granular é um aglutinante.
- 6. Formulação de droga, de acordo com a reivindicação 1, caracterizada pelo fato de que o excipiente intra-granular é:- uma combinação de pelo menos um diluente e pelo menos um desintegrante;- uma combinação de pelo menos um desintegrante e pelo menos um aglutinante; ou- uma combinação de pelo menos um diluente, pelo menos um desintegrante e pelo menos um aglutinante.
- 7. Formulação de droga, de acordo com a reivindicação 3, caracterizada pelo fato de que o desintegrante é selecionado a partir do grupo que consiste de povidona, crospovidona, carboximetilcelulose, metilcelulose, ácido algínico, croscarmelose sódica, glicolato de amido sódico, amido, formaldeído-caseína e combinações dos mesmos.
- 8. Formulação de droga, de acordo com a reivindicação 4, caracterizada pelo fato de que o diluente é selecionado a partir do grupo, que consiste de maltose, maltodextrina, lactose, frutose, dextrina, celulose microcristalina, amido préPetição 870180063227, de 23/07/2018, pág. 23/292/4 gelatinizado, sorbitol, sacarose, celulose microcristalina silicificada, celulose em pó, dextratos, manitol, fosfato de cálcio e combinações dos mesmos.
- 9. Formulação de droga, de acordo com a reivindicação 5, caracterizada pelo fato de que o aglutinante é selecionado a partir de um grupo, que consiste de acácia, dextrina, amido, povidona, carboximetilcelulose, goma guar, glicose, hidroxipropil metilcelulose, metilcelulose, polimetacrilatos, maltodextrina, hidroxietilcelulose e combinações dos mesmos.
- 10. Formulação de droga, de acordo com a reivindicação 1, caracterizada pelo fato de que os grânulos são produzidos através de granulação a seco.
- 11. Formulação de droga, de acordo com a reivindicação 1, caracterizada pelo fato de que os grânulos são produzidos através de granulação a úmido.
- 12. Formulação de droga, de acordo com a reivindicação 1, caracterizada pelo fato de que a formulação é uma cápsula, que compreende os grânulos encapsulados em um invólucro.
13. Formulação de droga, de acordo com a reivindicação 12, caracterizada pelo fato de que a formulação compreende um lubrificante extra- granular. 14. Formulação de droga, de acordo com a reivindicação 13, caracterizada pelo fato de que o lubrificante é selecionado a partir do grupo, que consiste de estearato de cálcio, estearato de magnésio, ácido esteárico, talco, óleo vegetal, poloxâmero, um óleo mineral, lauril sulfato de sódio, estearil fumarato de sódio, estearato de zinco e combinações dos mesmos. - 15. Formulação de droga, de acordo com a reivindicação 1, caracterizada pelo fato de que a formulação consiste em um comprimido, que compreende os grânulos em combinação com um ou mais excipientes extra-granulares.
- 16. Formulação de droga, de acordo com a reivindicação 15, caracterizada pelo fato de que o excipiente extra-granular é selecionado a partir do grupo, que consiste de um ou mais desintegrantes, um ou mais diluentes, um ou mais aglutinantes, um ou mais lubrificantes, e suas combinações.
- 17. Formulação de droga, de acordo com a reivindicação 16,Petição 870180063227, de 23/07/2018, pág. 24/293/4 caracterizada pelo fato de que o desintegrante extra-granular é selecionado a partir do grupo, que consiste de povidona, crospovidona, carboximetil celulose, metil celulose, ácido algínico, croscarmelose sódica, glicolato de amido sódico, amido, formaldeído-caseína, e combinações dos mesmos.
- 18. Formulação de droga, de acordo com a reivindicação 16, caracterizada pelo fato de que o diluente extra-granular é selecionado a partir do grupo, que consiste de maltose, maltodextrina, lactose, frutose, dextrina, celulose microcristalina, amido pré-gelatinizado, sorbitol, sacarose, celulose microcristalina silicificada, celulose em pó, dextratos, manitol, fosfato de cálcio e combinações dos mesmos.
- 19. Formulação de droga, de acordo com a reivindicação 16, caracterizada pelo fato de que o aglutinante extra-granular é selecionado a partir de um grupo, que consiste de acácia, dextrina, amido, povidona, carboximetil celulose, goma guar, glicose, hidroxipropil metilcelulose, metilcelulose, polimetacrilatos, maltodextrina, hidroxietil celulose e combinações dos mesmos.
- 20. Formulação de droga, de acordo com a reivindicação 16, caracterizada pelo fato de que o lubrificante extra-granular é selecionado a partir do grupo, que consiste de estearato de cálcio, estearato de magnésio, ácido esteárico, talco, um óleo vegetal, poloxâmero, um óleo mineral, lauril sulfato de sódio, estearil furamato de sódio, estearato de zinco e combinações dos mesmos.
- 21. Formulação de droga, de acordo com a reivindicação 2, caracterizada pelo fato de que 90% da substância da droga possui um tamanho de partícula inferior a 250 micrômetros, tamanho de partícula refere-se ao diâmetro da partícula, ou no caso em que as partículas não sejam esféricas, à maior extensão em uma direção da partícula.
- 22. Formulação de droga, de acordo com a reivindicação 21, caracterizada pelo fato de que 90% da substância da droga possui um tamanho de partícula inferior a 150 micrômetros e 50% da substância da droga possui um tamanho de partícula inferior a 25 micrômetros.
- 23. Formulação de droga, de acordo com a reivindicação 22,Petição 870180063227, de 23/07/2018, pág. 25/294/4 caracterizada pelo fato de que 90% da substância da droga possui um tamanho de partícula inferior a 50 micrômetros e 50% da substância da droga possui um tamanho de partícula inferior a 15 micrômetros.Petição 870180063227, de 23/07/2018, pág. 26/291/1......* * * * 1 » ♦ ··· · * : :·· ·· : : : : ··: :PERFIL DE DISSOLUÇÃOOCM oCMO to oCM oCO oCQ zÕQ_ εLUO <o <l oUJ alΞÜJ—I %
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/783,024 US8642079B2 (en) | 2004-02-23 | 2004-02-23 | Solid formulations of ospemifene |
PCT/FI2005/000037 WO2005079777A1 (en) | 2004-02-23 | 2005-01-19 | Solid formulations of ospemifene |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0507897A BRPI0507897A (pt) | 2007-07-24 |
BRPI0507897B1 true BRPI0507897B1 (pt) | 2018-10-09 |
BRPI0507897B8 BRPI0507897B8 (pt) | 2021-05-25 |
Family
ID=34861126
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0507897A BRPI0507897B8 (pt) | 2004-02-23 | 2005-01-19 | formulação de droga sólida |
Country Status (19)
Country | Link |
---|---|
US (2) | US8642079B2 (pt) |
EP (2) | EP2286806A1 (pt) |
JP (1) | JP4993203B2 (pt) |
CN (1) | CN1953741B (pt) |
AT (1) | ATE506054T1 (pt) |
AU (1) | AU2005215174B2 (pt) |
BR (1) | BRPI0507897B8 (pt) |
CA (1) | CA2554695C (pt) |
CY (1) | CY1111689T1 (pt) |
DE (1) | DE602005027540D1 (pt) |
DK (1) | DK1718288T3 (pt) |
ES (1) | ES2364970T3 (pt) |
MX (1) | MXPA06009546A (pt) |
NO (1) | NO341573B1 (pt) |
PL (1) | PL1718288T3 (pt) |
PT (1) | PT1718288E (pt) |
RU (2) | RU2423113C2 (pt) |
SI (1) | SI1718288T1 (pt) |
WO (1) | WO2005079777A1 (pt) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100777169B1 (ko) | 2001-01-29 | 2007-11-16 | 시오노기세이야쿠가부시키가이샤 | 5-메틸-1-페닐-2-(1h)-피리돈을 활성 성분으로서함유하는 의약 제제 |
US8236861B2 (en) | 2004-02-13 | 2012-08-07 | Hormos Medical Corporation | Method for enhancing the bioavailablity of ospemifene |
US8642079B2 (en) * | 2004-02-23 | 2014-02-04 | Hormos Medical Corporation | Solid formulations of ospemifene |
CN1950071A (zh) | 2004-05-04 | 2007-04-18 | 霍尔莫斯医疗有限公司 | ospemifene的新口服制剂 |
US8758821B2 (en) * | 2004-05-04 | 2014-06-24 | Hormos Medical Ltd. | Oral formulations of ospemifene |
NZ591443A (en) * | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
JP2009514944A (ja) * | 2005-11-09 | 2009-04-09 | ホルモス メディカル リミテッド | フィスペミフェン製剤 |
CA2563690C (en) * | 2006-10-12 | 2014-10-07 | Pharmascience Inc. | Pharmaceutical compositions comprising intra- and extra- granular fractions |
SI2121553T1 (sl) | 2007-02-14 | 2012-11-30 | Hormos Medical Ltd | Postopek za pripravo terapevtsko uporabnih trifenilbutenskih derivatov |
WO2008099060A2 (en) | 2007-02-14 | 2008-08-21 | Hormos Medical Ltd | Methods for the preparation of fispemifene from ospemifene |
CA2719608A1 (en) * | 2008-04-01 | 2009-10-08 | Ocean 1 806, Llc | Orodispersable formulations of phosphodiesterase-5 (pde-5) inhibitors |
US9321712B2 (en) | 2012-10-19 | 2016-04-26 | Fermion Oy | Process for the preparation of ospemifene |
CN104788300B (zh) * | 2014-01-22 | 2017-01-11 | 南京华威医药科技开发有限公司 | 欧司哌米芬多晶型 |
US20160000732A1 (en) * | 2014-07-02 | 2016-01-07 | Cadila Healthcare Limited | Oral pharmaceutical compositions of ospemifene |
US20160022604A1 (en) * | 2014-07-23 | 2016-01-28 | Cadila Healthcare Limited | Directly compressed ospemifene compositions |
US10138190B2 (en) | 2015-01-09 | 2018-11-27 | Glenmark Pharmaceuticals Limited | Process for preparation of ospemifene |
WO2016145138A1 (en) | 2015-03-10 | 2016-09-15 | Shionogi Inc. | Solid dispersions |
CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
WO2018140450A1 (en) * | 2017-01-24 | 2018-08-02 | Costigan Timothy E | Granulated feed supplement and methods for making and using |
RS63725B1 (sr) | 2020-05-18 | 2022-12-30 | Orexo Ab | Nova farmaceutska kompozicija za davanje leka |
AR127780A1 (es) | 2021-11-25 | 2024-02-28 | Orexo Ab | Nueva composición farmacéutica que comprende adrenalina |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4117121A (en) * | 1977-04-22 | 1978-09-26 | Hoffmann-La Roche Inc. | Method of increasing bile flow and decreasing lipid levels |
FI100692B (fi) | 1994-05-24 | 1998-02-13 | Leiras Oy | Menetelmä farmaseuttisten koostumusten valmistamiseksi, jolloin koostu mukset pohjautuvat mikroemulsiogeeleihin sekä uusia mikroemulsioihin p ohjautuvia geelejä |
GB9418067D0 (en) * | 1994-09-07 | 1994-10-26 | Orion Yhtymae Oy | Triphenylethylenes for the prevention and treatment of osteoporosis |
US6562862B1 (en) * | 1994-10-20 | 2003-05-13 | Eli Lilly And Company | Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y |
US5597582A (en) * | 1995-09-12 | 1997-01-28 | Sanofi | Oral gel capsule formulation of 1,2,4-benzotriazine oxides |
AU718417B2 (en) * | 1995-11-14 | 2000-04-13 | Stockhausen Gmbh & Co. Kg | Water additive and method for fire prevention and fire extinguishing |
GB9604577D0 (en) | 1996-03-04 | 1996-05-01 | Orion Yhtymae Oy | Serum cholesterol lowering agent |
FI101305B1 (fi) * | 1996-03-18 | 1998-05-29 | Map Medical Technologies Oy | Radiofarmaseuttisena aineena käyttökelpoiset radiojodatut bentsodiatsepiini-johdannaiset ja niiden käyttö diagnostiikassa |
DE19653736C2 (de) * | 1996-12-12 | 2002-11-21 | Lancaster Group Gmbh | Kosmetisches Präparat mit Peptidzusatz |
RU2112504C1 (ru) * | 1996-12-24 | 1998-06-10 | Открытое акционерное общество "Нижегородский химико-фармацевтический завод" | Средство для лечения заболеваний предстательной железы "витапрост" |
US6525084B2 (en) * | 1998-07-23 | 2003-02-25 | Novo Nordisk A/S | Stable pharmaceutical formulation |
AU5026599A (en) * | 1998-07-23 | 2000-02-14 | Novo Nordisk A/S | A wet granulation method for preparing a stable pharmaceutical formulation |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US6245352B1 (en) * | 1999-04-27 | 2001-06-12 | Eli Lilly And Company | Pharmaceutical formulation |
US6245819B1 (en) * | 2000-07-21 | 2001-06-12 | Hormos Medical Oy, Ltd. | Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause |
US6838484B2 (en) * | 2000-08-24 | 2005-01-04 | University Of Tennessee Research Foundation | Formulations comprising selective androgen receptor modulators |
WO2002056903A2 (en) * | 2001-01-17 | 2002-07-25 | Praecis Pharmaceuticals Inc. | Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators |
RU2177802C1 (ru) * | 2001-01-25 | 2002-01-10 | Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн" | Тетрапептид, регулирующий функции предстательной железы, фармакологическое средство на его основе и способ его применения |
US20030055075A1 (en) * | 2001-07-13 | 2003-03-20 | Rubsamen Reid M. | Programmable controlled release injectable opioid formulation |
WO2003015820A1 (fr) | 2001-08-10 | 2003-02-27 | Takeda Chemical Industries, Ltd. | Medicaments combines d'agoniste de la gnrh |
HUP0202719A3 (en) * | 2001-08-21 | 2006-01-30 | Pfizer Prod Inc | Pharmaceutical compositions for the treatment of female sexual dysfunctions |
CA2484542C (en) | 2002-06-06 | 2010-11-02 | Hormos Medical Corporation | Method for the inhibition of atrophy or for treatment or prevention of atrophy-related symptoms in women |
US7407965B2 (en) * | 2003-04-25 | 2008-08-05 | Gilead Sciences, Inc. | Phosphonate analogs for treating metabolic diseases |
US8236861B2 (en) * | 2004-02-13 | 2012-08-07 | Hormos Medical Corporation | Method for enhancing the bioavailablity of ospemifene |
US8642079B2 (en) | 2004-02-23 | 2014-02-04 | Hormos Medical Corporation | Solid formulations of ospemifene |
US20060105045A1 (en) * | 2004-11-08 | 2006-05-18 | Buchanan Charles M | Cyclodextrin solubilizers for liquid and semi-solid formulations |
EA010427B1 (ru) * | 2007-04-27 | 2008-08-29 | Открытое Акционерное Общество "Нижегородский Химико-Фармацевтический Завод" (Оао "Нижфарм") | Средство для лечения заболеваний предстательной железы |
RU2430733C2 (ru) * | 2009-10-08 | 2011-10-10 | Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") | Фармацевтическая композиция для лечения заболеваний предстательной железы (варианты) |
-
2004
- 2004-02-23 US US10/783,024 patent/US8642079B2/en active Active
-
2005
- 2005-01-19 DK DK05708125.9T patent/DK1718288T3/da active
- 2005-01-19 JP JP2007500233A patent/JP4993203B2/ja active Active
- 2005-01-19 AU AU2005215174A patent/AU2005215174B2/en active Active
- 2005-01-19 DE DE602005027540T patent/DE602005027540D1/de active Active
- 2005-01-19 SI SI200531330T patent/SI1718288T1/sl unknown
- 2005-01-19 MX MXPA06009546A patent/MXPA06009546A/es active IP Right Grant
- 2005-01-19 EP EP10180718A patent/EP2286806A1/en not_active Withdrawn
- 2005-01-19 CN CN2005800049727A patent/CN1953741B/zh active Active
- 2005-01-19 PL PL05708125T patent/PL1718288T3/pl unknown
- 2005-01-19 EP EP05708125A patent/EP1718288B1/en active Active
- 2005-01-19 WO PCT/FI2005/000037 patent/WO2005079777A1/en active Application Filing
- 2005-01-19 RU RU2006133902/15A patent/RU2423113C2/ru active
- 2005-01-19 PT PT05708125T patent/PT1718288E/pt unknown
- 2005-01-19 CA CA2554695A patent/CA2554695C/en active Active
- 2005-01-19 ES ES05708125T patent/ES2364970T3/es active Active
- 2005-01-19 AT AT05708125T patent/ATE506054T1/de active
- 2005-01-19 RU RU2011112362A patent/RU2675624C2/ru not_active Application Discontinuation
- 2005-01-19 BR BRPI0507897A patent/BRPI0507897B8/pt not_active IP Right Cessation
-
2006
- 2006-09-20 NO NO20064262A patent/NO341573B1/no unknown
-
2011
- 2011-07-14 CY CY20111100689T patent/CY1111689T1/el unknown
-
2014
- 2014-01-30 US US14/168,842 patent/US20140220118A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP4993203B2 (ja) | 2012-08-08 |
BRPI0507897B8 (pt) | 2021-05-25 |
SI1718288T1 (sl) | 2011-09-30 |
AU2005215174A1 (en) | 2005-09-01 |
NO20064262L (no) | 2006-09-20 |
EP2286806A1 (en) | 2011-02-23 |
NO341573B1 (no) | 2017-12-04 |
EP1718288A1 (en) | 2006-11-08 |
WO2005079777A1 (en) | 2005-09-01 |
MXPA06009546A (es) | 2007-04-10 |
US8642079B2 (en) | 2014-02-04 |
AU2005215174B2 (en) | 2010-06-03 |
CY1111689T1 (el) | 2015-10-07 |
US20140220118A1 (en) | 2014-08-07 |
PL1718288T3 (pl) | 2011-10-31 |
BRPI0507897A (pt) | 2007-07-24 |
US20050187301A1 (en) | 2005-08-25 |
CN1953741A (zh) | 2007-04-25 |
DK1718288T3 (da) | 2011-08-01 |
CN1953741B (zh) | 2011-03-30 |
JP2007523210A (ja) | 2007-08-16 |
RU2675624C2 (ru) | 2018-12-21 |
DE602005027540D1 (de) | 2011-06-01 |
CA2554695C (en) | 2013-03-05 |
RU2006133902A (ru) | 2008-03-27 |
ES2364970T3 (es) | 2011-09-19 |
ATE506054T1 (de) | 2011-05-15 |
RU2423113C2 (ru) | 2011-07-10 |
EP1718288B1 (en) | 2011-04-20 |
CA2554695A1 (en) | 2005-09-01 |
RU2011112362A (ru) | 2012-10-10 |
PT1718288E (pt) | 2011-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0507897B1 (pt) | formulação de droga sólida | |
RU2492853C2 (ru) | Таблетки на основе улипристала ацетата | |
TW201815384A (zh) | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 | |
JP5758904B2 (ja) | ニトライトの医薬製剤及びそれらの使用 | |
JP6121990B2 (ja) | 薬物送達システム | |
US20060240101A1 (en) | Orally disintegrating pharmaceutical tablet formulations of olanzapine | |
EA008196B1 (ru) | Твердая лекарственная форма для перорального применения | |
BRPI0713935A2 (pt) | formulações em comprimido de liberação imediata de um antagonista de receptor de trombina | |
CN104398481A (zh) | 比拉斯汀口崩片及其制备方法 | |
BR112015025058B1 (pt) | Composição farmacêutica do tipo matriz contendo lacosamida | |
Sahu et al. | Formulation and evaluation of sustain released matrix tablet of atenolol | |
TW201138767A (en) | Solid pharmaceutical fixed dose compositions comprising ramipril and amlodipine, and their preparation | |
KR20220029717A (ko) | 항암 화합물 e7766의 치료 순응도 향상을 위한 시스템 | |
Koli et al. | Formulation And Evaluation Of Berberine Hydrochloride Film Coated Tablet | |
CN106474095B (zh) | 一种用于治疗口腔真菌的口腔粘膜粘贴剂及其制备方法 | |
Abd El-Bary et al. | Formulation and evaluation of Sertraline HCl sublingual oral disintegrating tablets using factorial design | |
KR20070032298A (ko) | 오스페미펜의 고체 제제 | |
CN106692067B (zh) | 双嘧达莫固体分散体、口崩片及其制备方法 | |
Srilalitha et al. | Design and characterization of fast release sublingual tablets of atenolol | |
RU2537169C1 (ru) | Фармацевтическая композиция, содержащая дезлоратадин (варианты) | |
Abbas et al. | Formulation and Evaluation of Orodispersible tablet of Nifedipine 5 mg. | |
AHMED | GASTRO RETENTIVE SYSTEMS FOR EFFECTIVE DELIVERY OF CAPTOPRIL AND DILTIAZEM | |
BG65912B1 (bg) | Лекарствена форма на комбиниран препарат и метод за нейното получаване | |
CN101461810A (zh) | 一种含有拉呋替丁的口服固体药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/10/2018, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/01/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 19A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2758 DE 14-11-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |